Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
YOU ARE SPOT ON!
yeah, if i held this debt, i'd be pissed
Senior secured debt, in default
$
14,416k
while kevvy wevvy is making 600k
Kevin A. Richardson, II Chief Executive Officer
he gets paid a fuck of a lot for VERY little payout to investors
who the fuck is on the board anyway?????????????????????????????????????/
Year
Salary (1)
All other
compensation (2)
Total
2022
430,583
175,000
605,583
https://www.sec.gov/ix?doc=/Archives/edgar/data/1417663/000114036123015331/brhc10050349_10k.htm
Common stock, par value $0.001, 2,500,000,000 shares authorized, 548,737,651 and 481,619,621 issued and outstanding at 2022 and 2021, respectively
Kelly I thought you were smarter than that
Common stock, par value $0.001, 2,500,000,000 shares authorized, 548,737,651 and 481,619,621 issued and outstanding at 2022 and 2021, respectively
Are you an obfuscator
That's completely wrong. Look at the most recent filings on the sec website.
and from Yahoo
Share Statistics
Avg Vol (3 month) 342.9k
Avg Vol (10 day) 591.74k
Shares Outstanding 558.64M
source WSJ
Market Cap
$13.35 M
Shares Outstanding
558.64 M
Public Float
522.99 M
as of this moment ...
Shares outstanding 558,637,651
times
$0.0285
=
$15,921,173, which is the mkt cap of the company
(not 2.5bb x $0.0285, which would be a 71mm mkt cap)
you can prove me wrong with facts from some source i am not seeing
Market cap.Micro Cap ($13.35M)
Shares outstanding 558,637,651
Ppl are intentionally obfuscating Outstanding and Authorized
https://www.investopedia.com/ask/answers/011315/what-difference-between-authorized-shares-and-outstanding-shares.asp
2.5bb AUTHORIZED
If so, anyone ever go to that location ?
Thanks in advance
Another question, are all operations now run out of MN location?
Left a message for our Chairman, Morgan Frank to call me. Never spoke to him before so will see if I get a reply.
Anyone have a transcript from the last CC ?
I believe with the most recent $$ raise there are close to 2.5 billion shares outstanding.
Anyone know the exact number of shares outstanding now? I think there are close to 2.5 billion now.
Utterly ridiculous.
WTF is going on with this stock!
CEO must GO
CEO most GU
somebody took a big dump on that to end the week
mkt cap is Micro Cap ($19.27M)
on ttm revenues of 16.7mm
20% growth is $20.0mm
stock is trading 1x forward revenues ...
Ich, mgmt says Q1 will be +20% from a year ago. Year ago was $3.2mm. +20% is $3.84mm. if they dont make that someone needs to take this out back and shoot it; Q4 2022 was $5.5mm.
why is that soooooo alarming/
Did everyone see the alarming 8-K published Friday after hours?
On March 28, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of SANUWAVE Health, Inc. (the “Company”) after discussion with management concluded that the interim financial statements contained in the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022 (the “Form 10-Qs”) should no longer be relied upon for the reasons summarized below.
https://www.otcmarkets.com/filing/html?id=16534150&guid=bwm-ke_QP5kVV3h
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 28, 2023
SANUWAVE Health, Inc.
(Exact name of registrant as specified in its charter)
Nevada
000-52985
20-1176000
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
11495 Valley View Road, Eden Prairie, Minnesota
55344
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code
(770) 419-7525
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
?
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
?
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
N/A
N/A
N/A
Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 4.02
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.
On March 28, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of SANUWAVE Health, Inc. (the “Company”) after discussion with management concluded that the interim financial statements contained in the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022 (the “Form 10-Qs”) should no longer be relied upon for the reasons summarized below.
In connection with preparing its financial statements for the year ended December 31, 2022, the Company identified several accounting misstatements and as such is restating the interim financial statements in the Form 10-Qs to correct (i) an inventory conversion error during the quarter ended September 30, 2022; (ii) a failure to recognize (a) professional fee invoices during each of the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022, (b) advisory shares during the quarter ended June 30, 2022; and (c) interest expense on the Senior Secured Promissory Note Payable issued by the Company to NH Expansion Credit Fund Holdings LP during the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022; and (iii) improper recording of a financing lease arrangement during the quarters ended March 31, 2022 and June 30, 2022.
The Company and its advisors completed the annual review, and the Company will file the restated financial statements as of March 31, 2022, June 30, 2022 and September 30, 2022 and for the three months ended March 31, 2022, the three and six months ended June 30, 2022 and the three and nine months ended September 30, 2022 in its Annual Report on Form 10-K for the year ending December 31, 2022.
The Audit Committee and Company management have discussed the matters disclosed on this Current Report on Form 8-K with the Company’s independent registered public accounting firm, Marcum LLP.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SANUWAVE HEALTH, INC.
Dated: March 31, 2023
By:
/s/ Toni Rinow
Name:
Toni Rinow
Title:
Chief Financial Officer
As of close of biz Friday :
Mkt cap is 23mm
TTM sales is 16.7mm
4x sales is 67ish mm
Should be about a 3x share price from here
????
They’ve been trading roughly 1x revenue maybe this increase will show some stability and get to a 3x-4x?
I think the bigger issues are the outstanding late notes. They are in a shitstorm of debt
First of all, there are now more than 2 billion shares after the last increase.
Second of all, this stock isn’t trading at x10-20 revenue like a normal medical devise because Kevin Richardson is running the show and he has a history of misleading and false statements, over promising and under delivering, not paying his employees and vendors, and cratering relationships.
Sanuwave would see an instant surge in share price if Kevin was removed as CEO and someone else was brought in to run the company.
Sorry, 5.6 million
For the Years Ended December 31,
Change
(in thousands)
2022
2021
$
%
Revenue
16,742
$
13,010
$
3,732
29
%
Cost of revenue
4,331
4,986
(655
)
-13
%
Gross margin
12,411
8,024
4,387
55
%
Operating expenses:
General and administrative
12,556
11,690
866
7
%
Selling and marketing
7,474
8,591
(1,117
)
-13
%
Research and development
567
1,101
(534
)
-49
%
Depreciation and amortization
766
784
(18
)
-2
%
Operating loss
(8,952
)
(14,142
)
5,190
-37
%
Other income (expense), net
(1,339
)
(13,089
)
11,750
-90
%
Income tax expense
2
28
(26
)
-93
%
Net loss
$
(10,293
)
$
(27,259
)
$
16,966
-62
%
9 month rev until q3 was 11.2.
I don’t see that anywhere
Where did u see the 5.8 number
Revenue ramped up to 5.8 million in q4.
Q3 revenue was 4.2.
That is extremely impressive considering 4q is quite slow with holiday season.
So with that much revenue growth and the prospect of being cash flow positive this half year, why is it not trading at 10* revenue, a standard for medical device?
That would put it at 200 million. For say 1 billion shares, that would be around .2 share price.
a call??? WTF??? no slides or visuals??? this could be a giant suckfest
SANUWAVE Will Host a Live Conference Call and Webcast April 3, 2023 at 9:00 AM to Provide a Financial and Business Update
GLOBENEWSWIRE
10:24 AM ET 03/30/2023
Eden Prairie, MN, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (SNWV) , a leading provider of next-generation wound care products, will host a live conference call on Monday, April 3, 2023, at 9:00AM (EDT) to discuss a financial update and recent strategic initiatives.
Telephone access to the call will be available by dialing the following numbers:
Participant Listening: 1-877-407-0784 or 1-201-689-8560
OR click the Call me™ link for instant telephone access to the event.
Call me™:
https://callme.viavid.com/viavid/?callme=true&passcode=13732361&h=true&info=company&r=true&B=6
A replay will be made available through April 17, 2023:
Toll-Free: 1-844-512-2921 or 1-412-317-6671
Replay Access ID: 13737646
i'd like to take a chunk of this in the 2s, yeh, it an go to zero, but at 2 they are trading below 1x revenue. i am guessing the mkt thinks this will go belly up. ANY news tomorrow will be positive
Ohhh got it. We’ll see. We’ll see.
It’s available on their website
It was in the Q3 report from November 15 last year
Where r u getting this? Is this ur guess? Inside info? Corp release somewhere?
Where r u getting this? Is this ur guess? Inside info? Corp release somewhere?
2022 REVENUE GUIDANCE
REVENUE GUIDANCE: $17-18 Million (vs $13 Million 2021, +31-39%)
We will know in 2 days
i kinda hava feelin its do or die this week for old SNWV, Q4 numbers need tp be out by friday
let's see iff kevvy wevvy can deliver ...
2022 REVENUE GUIDANCE:
$17-18 Million (vs $13 Million 2021, +31-39%) - they were 11.2 at end Q3
Break Even $1.8mm/mo
Gross Margin 75%
Opex $1.4mm/mo
Market Cap is currently, barely 1x revenue